MANI surges as H1 operating profit jumps 22%, beats prior guidance

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Apr 15, 2026 10:18 am JST Catalyst

MANI <7730> rebounded sharply to hit a new year-to-date high on Wednesday. Following the market close on the 14th, the surgical instrument maker reported consolidated results for the first half ended February, with sales reaching 16.106 billion yen (up 8.7% year-on-year) and operating profit hitting 5.097 billion yen (up 22.2%). The result significantly exceeded the company's previous operating profit forecast of 4.3 billion yen. Net profit rose 32.6% to 3.898 billion yen.

The performance was bolstered by the continued weakness of the yen, which lifted overseas revenue, alongside strong growth in dental products. Specifically, the resumption of diamond bur sales in China and increased orders at German subsidiary MMG supported the bottom line. Eyeless needle products also saw robust demand in Asian markets, particularly in China, Thailand, and India. Foreign exchange gains from the yen’s depreciation further contributed to the strong results.

Mani maintained its full-year earnings forecast for the fiscal year ending August 2026, projecting sales of 32.8 billion yen (up 9.4%), operating profit of 9.2 billion yen (up 12.3%), and net profit of 6.45 billion yen (up 38.9%).

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.